Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
AARTIDRUGS
Mr. Prakash Moreshwar Patil · Mumbai, India
₹411.25
▲+0.72%Aarti Drugs trades near the upper end of its 52-week range (~411 INR vs 549 high) at a reasonable 19x P/E, but low institutional ownership (11%) and 6.4% revenue growth suggest muted market conviction despite steady margins and moderate ROE.
Exchange
NSI
Currency
INR
Day range
₹406.40 – ₹415.00
52-week range
₹318.95 – ₹549.30
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis62% confidence
A fair-value estimate is roughly in the 380–440 INR band, implying the current 411 INR is approximately at intrinsic value — not deeply cheap, but not stretched either — given its moderate growth profile.
25.1% below the 1-year high · trend up
Hedge-fund memo
Today
Traded in a tight 406–415 range with a modest 0.72% gain on moderate volume of ~129K, indicating routine day-to-day activity.
This week
Price is sitting in the upper third of its 52-week range (319–549), suggesting some post-correction recovery from the 52-week low but well below the high.
This month
Institutional ownership remains low at 11.10%, and the absence of analyst coverage means institutional re-interest is a key catalyst to watch.
Bull thesis
Bear thesis
Narrative read
Neutral
Composite sentiment
Institutional
Underweight at 11.10% — institutions are not positioned here, which limits bid support but also means less selling pressure
Retail
Moderate participation with thin but consistent daily volume; no signs of speculative frenzy
News flow
No notable catalysts or adverse headlines in the immediate window
Read
Absence of analyst consensus coverage is a double-edged sword — less noise but also less visibility for the stock
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 1 recent quarters (EPS actual vs. consensus).
4.95 vs 4.9
1.02% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| AARTIDRUGS | 37.53B | 19.26 | 13.36% | 10.90% | 6.40% |
| IOLCP | 43.25B | 31.42 | 7.90% | 11.65% | 17.40% |
| LAURUSLABS | 962.46B | 88.05 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
USFDA or EMA regulatory action on manufacturing sites disrupting export approvals
Mitigation: Diversify across multiple FDA-approved facilities; monitor FDA inspection calendars
Raw material / starting material cost inflation squeezing API margins
Mitigation: Long-term supplier contracts and vertical backward integration where feasible
Price erosion from Chinese API competitors in non-regulated markets
Mitigation: Focus on regulated-market contracts and complex/harder-to-make APIs where quality commands premium
Business intelligence
Competitive moat
Moderate — Aarti's competitive advantage stems from experience in manufacturing niche and complex APIs, regulatory approvals for controlled substances, and established compliance certifications (FDA, EMA) that create barriers for newer entrants in those specific molecules.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
Catalyst calendar
QoQ revenue and gross margin trends will signal export demand health
New USDMF / DMF filings or ANDA approvals for key molecules could trigger re-rating
Potential strategic partnerships or divestiture of non-core API lines to streamline portfolio
Thesis builder
Bull case
Export-led API margin expansion from supply-chain diversification away from China, combined with new product approvals in regulated markets, could drive 12–15% annual earnings growth over 3 years.
Base case
Steady-state growth of 8–10% CAGR in revenue with stable ~7–8% net margins, supporting a 15–20x P/E range and flat-to-modest price appreciation.
Bear case
Chinese API underscutting, raw material inflation, or a USFDA warning letter could compress margins to the mid-5% range and compress the valuation multiple to 13–15x.
Time horizon
Medium-term (18–36 months) thesis depends on export mix shift toward regulated markets and margin resilience.
Est. CAGR
8–12% revenue CAGR (approx)
Entry (qual.)
380–400 INR offers a more comfortable entry than the current level; 411 is fair but not a clear discount.
Exit (qual.)
Consider partial profit-booking above 480–500 INR unless margin expansion materially exceeds expectations.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how AARTIDRUGS fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain AARTIDRUGS for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Hold with a cautious tilt — the stock offers a reasonable valuation but lacks the growth momentum or institutional backing to justify an aggressive position at current levels.
Annual income statement, oldest → newest. Live via Yahoo.
| — |
| 25.39% |
| 29.10% |
| APLLTD | 159.60B | 23.67 | 12.36% | 7.39% | 4.40% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹406.40
Resistance (day/52w high)
₹415.00
Volume
1,28,814
Trend
up
RSI (14)
60
MACD
bearish
MA cross
death
50-day MA
₹387.53
200-day MA
₹392.19
vs 200-DMA
4.9%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Low institutional ownership leading to volatile stock reactions to news/sentiment
Mitigation: Longer holding horizon to ride out retail-driven volatility
M&A / strategic moves
Overall conviction 62%